Fig. 2From: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC studyKaplan–Meier plots of DOR (a), PFS (b), and OS (c) by investigator assessment. DOR, duration of response; laBCC, locally advanced basal cell carcinoma; mBCC, metastatic basal cell carcinoma; OR, overall survival; PFS, progression-free survivalBack to article page